By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Myriad Genetics, Inc. 

320 Wakara Way

Salt Lake City  Utah  84108  U.S.A.
Phone: 801-584-3600 Fax: 801-584-3640


Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.


May 1991


CEO and Founder: Mark Capone

CMO (Medical): Richard Wenstrup

CFO: Bryan Riggsbee

CSO (Scientific): Jerry Lanchbury


Please click here for Myriad Genetics job opportunities.


Please click here for clinical trial information.


All Products


Key Statistics

Ownership: Public

Web Site: Myriad Genetics
Symbol: MYGN

Company News
Myriad Genetics (MYGN) Announces Positive Data Supporting New riskScore Test At The 36th Annual Conference Of The National Society Of Genetic Counselors 9/15/2017 8:04:24 AM
Myriad Genetics (MYGN) To Present Three Studies At The 2017 National Society Of Genetic Counselors Annual Conference 9/13/2017 11:46:09 AM
Myriad Genetics (MYGN) Release: Hereditary Cancer Risk Assessment Is An Important Option For Prostate Cancer Patients During Prostate Cancer Awareness Month 9/7/2017 8:42:42 AM
Myriad Genetics (MYGN) Launches riskScore Beginning The Next Epoch In Hereditary Cancer Testing 9/6/2017 8:08:09 AM
Myriad Genetics (MYGN) Release: Endopredict Receives Positive Coverage Decisions From Medicare And Anthem 8/18/2017 7:47:47 AM
Myriad Genetics (MYGN) Reports Fiscal Fourth-Quarter 2017 And Fiscal Full-Year 2017 Financial Results 8/9/2017 1:31:32 PM
Myriad Genetics (MYGN) To Announce Fiscal Fourth-Quarter 2017 Financial Results On August 8, 2017 7/31/2017 12:57:51 PM
Myriad Genetics (MYGN)’s BRACAnalysis CDx Test Identified Patients With Metastatic Breast Cancer Who Benefited From Treatment With Olaparib In Phase III OlympiAD Study 6/5/2017 9:59:12 AM
Myriad Genetics (MYGN) Announces 17 Additional Health Insurance Plans Covering EndoPredict 6/5/2017 9:58:12 AM
Myriad Genetics (MYGN) Announces Results From A Large 2,000 Patient Clinical Utility Study Of Its Myrisk® Hereditary Cancer Test At The 53rd Annual Meeting Of ASCO 6/2/2017 7:36:54 AM